Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2000; 35(11): 677-684
DOI: 10.1055/s-2000-8161
ÜBERSICHT
ORIGINALIA
© Georg Thieme Verlag Stuttgart · New York

Nicht-Opioid-Analgetika - unersetzlich in der Tumorschmerztherapie?

E. Ladner1 , R. Plattner1 , B. Friesenecker2 , J. Berger2 , F. Javorsky3
  • 1Abteilung für Anästhesie, Bezirkskrankenhaus Reutte
  • 2Univ.-Klinik für Anästhesie und Allgemeine Intensivmedizin, Leopold-Franzens-Universität Innsbruck
  • 3Abt. für Anästhesie und Intensivmedizin, SMZ Ost Wien
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung.

Eine ausreichende Therapie der Schmerzen hat für Tumorpatienten höchste Priorität. WHO-Richtlinien schlagen eine - in der deutschsprachigen Literatur obligate - Kombination von Opioiden mit Nichtopioid-Analgetika (NOA) für Patienten mit mittleren bis starken Schmerzen vor. Tumorschmerzen können durch den Tumor selbst verursacht, tumorassoziiert, therapiebedingt sowie therapieunabhängig sein, und nur durch eine Kombinationstherapie von Opioiden mit NOA, wie den Cyclooxygenase-Inhibitoren (nicht-steroidalen Antirheumatika = NSAR) beherrscht werden. Eine Kombination von Opioiden mit Nichtopioidanalgetika bringt, unter Wahrung von Vorsichtsmaßnahmen, eine bessere Effizienz bei akzeptablem Risikoprofil.

Non-opioid-analgesics - irreplaceable in cancer pain therapy?

Sufficient therapy of pain is essential for the treatment of tumor patients. World Health Organisation (WHO)-guidelines recommend a combination of opioids with non-opioid-analgesics (NOA) for patients with medium to strong pain. Cancer pain is often a combination of pain caused by the tumor itself, tumor associated and pain caused by therapy. Various substances act by different mechanisms and therefore combinations may demonstrate superior effects. Opioids („central analgesics”) inhibit neuronal transduction within the spinal cord, enhance inhibiting function of midbrain nuclei on ascending pain transduction and influence pain perception via modulation of the limbic system. NOAs („peripheral analgesics”) inhibit cyclooxygenase hindering activation of the peripheral nociceptorsystem. There are 2 different classes of NOAs: 1) non-acidic, antipyretic analgesics like pyrazolones (metamizol) and anilin-derivates (paracetamol) and 2) non-steroidal antirheumatics (NSAR) like salicylates (acetylsalicylic acid), derivates of propionic acid (ibuprofen, naproxen), acetate acid (indomethacin, diclofenac), enolic acid (piroxicam, meloxicam) and anthranil acid (mefenamin). Adjuvant therapy is necessary to control common NSAR-side-effects like dyspepsia, ulcer and gastrointestinal bleeding. Due to its exceptional analgesic, antipyretic and spasmolytic properties, metamizol is an essential substance in tumor therapy. As agranulocytosis-incidence of 1:1.000.000 is low, good gastrointestinal and renal tolerance makes metamizol an excellent alternative to NSAR. There is scientific evidence that adequate combinations of non-opioids, opioids and adjuvant drugs, considering adverse side effects, were effective and safe in the treatment of cancer pain.

Schlüsselwörter:

Tumor-Schmerz - Nicht-opioid-Analgetika - Opioide

Key words:

Tumor pain - Non-opioid-analgesics - Opioids - Metamizol

Literaturverzeichnis

  • 1 Agrawal N M, Roth S, Graham D Y. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial.  Ann Intern Med. 1991;  115 195
    PubMedGoogle Scholar
  • 2 Alpermann H G, Scholtholt J. Pharmacology of dipyrone. Internal Report Hoechst AG, Pharma Research, Pharmacology, Document No.: 002 601 Nov./1982: F1-F36
    Google Scholar
  • 3 Arisz L, Donker A JM, Brentjens J RH, van der Hem G K. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome.  Acta Med Scand. 1976;  199 121
    PubMedGoogle Scholar
  • 4 Armstrong C P, Blower A L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.  Gut. 1987;  28 527
    CrossrefPubMedGoogle Scholar
  • 5 Bannwarth B, Demotes-Mainard F, Schaeverbeke T, Labat L, Derhaus J. Central analgesic effect of aspirin-like drugs.  Fundam Clin Pharmacol. 1995;  9 1
    PubMedGoogle Scholar
  • 6 Bardhan K D, Bjarnason I, Scott D L. The prevention and healing of acute nonsteroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol.  Br J Rheum. 1993;  32 990
    PubMedGoogle Scholar
  • 7 Beckmann M L, Gerber J G, Bynny R L. Propanolol increases prostacyclin synthesis in patients with hypertension.  Hypertension. 1988;  12 582
    PubMedGoogle Scholar
  • 8 Bigard M A. Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects [abstract].  Gastroenterology. 1988;  94 A34
    PubMedGoogle Scholar
  • 9 Bolton W, Brodenfeldt R. Efficiacy of Misoprostol in the therapy of NSAID-induced symptoms and lesions of the upper GI-tract under continued NSAID medication[abstract].  Clin Exp Rheumatol. 1990;  8 ((S4)) 59P
    PubMedGoogle Scholar
  • 10 Bolton W. Treatment of NSAID-induced gastrointestinal complaints by co-medication of the prostaglandin analog misoprostol in rheumatoid arthritis patients; a multicenter, double-blind, placebo-controlled study.  Akt Rheumatol. 1989;  14 214
    PubMedGoogle Scholar
  • 11 Bridoux F, Hazzan M, Pallot J L. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.  Nephrol Dial Transplant. 1992;  7 100
    PubMedGoogle Scholar
  • 12 Brune K, Peskar B A. Modulation by drugs of leucotriene and prostaglandin production from mouse peritoneal macrophages.  Int J Tissue React. 1985;  7 ((2)) 97
    PubMedGoogle Scholar
  • 13 Carlsson K H, Helmreich J, Jurna I. Comparison of central antinociceptive and analgetic effects of the pyrazolone derivates, metamizol (dipyrone) and aminophenazone („Pyramidon”).  Schmerz-Pain-Doleur. 1986;  7 93
    PubMedGoogle Scholar
  • 14 Carlsson K H, Jurna I. The role of descending inhibition in the antinociceptive effects of the pyrazolone derivates, metamizol (dipyrone) and aminophenazone („Pyramidon”).  Naunyn-Schmiedeberg's Arch Pharmacol. 1987;  335 154
    PubMedGoogle Scholar
  • 15 Clive D M, Stoff J S. Renal syndromes associated with anti-inflammatory drugs.  New Engl J Med. 1984;  310 563
    PubMedGoogle Scholar
  • 16 Dajani E Z, Wilson D E, Agrawal N M. Prostaglandins: an overview of the worldwide clinical experience.  J Assoc Acad Minor Phys. 1991;  2 ((1)) 23,27
    PubMedGoogle Scholar
  • 17 De Witt D, Smith W L. Yes, but they still got headaches?.  Cell. 1995;  83 ((22)) 345
    CrossrefPubMedGoogle Scholar
  • 18 Dinchuk J E, Car B D, Focht J, Johnston J J, Jaffee B D, Covington M B, Contel N R, Eng V M, Collins R J, Czerniak P M, Gorry S A, Trzaskos J M. Renal abnormalities and an altered inflammatory response in mice lacking cycloxygenase II.  Nature. 1995;  378 ((23)) 406
    CrossrefPubMedGoogle Scholar
  • 19 Dubois R N, Abramson S B, Crofford L, Gupta R A. Cyclooxygenase in biology and disease.  FASEB J. 1198;  12 ((12)) 1063-1073
    PubMedGoogle Scholar
  • 20 Ehsanullah R SB, Page M C, Tildesley G. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine.  BMJ. 1988;  297 1017
    PubMedGoogle Scholar
  • 21 Eisenberg E, Berkey C S, Carr D B, Mosteller F, Chalmers T C. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis.  J Clin Oncol. 1994;  12 2756
    PubMedGoogle Scholar
  • 22 Farah D, Sturrock R D, Russel R I. Peptic ulcers in rheumatoid arthritis.  Ann Intern Med. 1988;  47 472
    PubMedGoogle Scholar
  • 23 Freston M S, Freston J W. Peptic ulcers in the elderly: unique features and management.  Geriatrics. 1990;  45 39
    PubMedGoogle Scholar
  • 24 Gabriel S E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis.  Ann Intern Med. 1991;  115 787
    PubMedGoogle Scholar
  • 25 Gardella S, Maltarese R A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents.  Medicine (Baltimore). 1984;  63 165
    PubMedGoogle Scholar
  • 26 Geis G S, Stead H, Wallemark C B. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with RA or OA, and interim report on prevention of diclofenac-associated lesions.  J Rheumatol. 1991;  18 ((Suppl. 28)) 11
    PubMedGoogle Scholar
  • 27 Goodlad R A, Madgwick A J, Moffatt M R, Levin S, Allen S J, Wright N A. The effects of the prostaglandin analogue, misoprostol, on cell proliferation and cell migration in the canine stomach.  Digestion. 1990;  46 ((Suppl. 2)) 182
    PubMedGoogle Scholar
  • 28 Graham D J, Agrawal N M, Roth S H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.  Lancet. 1988;  II 1277
    PubMedGoogle Scholar
  • 29 Graham D J, White R H, Moreland L W. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs.  Ann Intern Med. 1993;  119 257
    PubMedGoogle Scholar
  • 30 Griffin M R, Ray W A, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons.  Ann Intern Med. 1988;  109 359
    PubMedGoogle Scholar
  • 31 Grond S, Zech D, Dahlmann H, Schug S A, Stobbe B, Lehmann K A. Überweisungsgrund: „therapieresistente” Tumorschmerzen.  Der Schmerz. 1990;  4 193-200
    PubMedGoogle Scholar
  • 32 Grond S, Zech D, Horrichs-Haermeyer G, Lehmann K A. Schmerztherapie in der Finalphase maligner Erkrankungen.  Der Schmerz. 1990;  4 22-28
    PubMedGoogle Scholar
  • 33 Grond S, Zech D, Schug S A, Lynch J, Lehmann K A. The importance of non opioid analgesics for cancer pain relief according to the guidelines of the world health organisation.  Int J Clin Pharm Res. 1991;  11 ((6)) 253
    PubMedGoogle Scholar
  • 34 Hanks G W, Justins D M. Cancer pain: management.  Lancet. 1992;  339 1031
    CrossrefPubMedGoogle Scholar
  • 35 Hawkey C, Kahan A, Steinbruck K. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group.  Br J Rheumatol . 1998;  37 ((9)) 937-945
    CrossrefPubMedGoogle Scholar
  • 36 Hayllar J, Bjarnason I. NSAIDs, Cox- 2 inhibitors, and the gut.  Lancet. 1995;  346 521
    CrossrefPubMedGoogle Scholar
  • 37 He X, Neugebauer V, Schaible H G, Schmidt R F. New aspects of the mode of action of dipyrone. In: Brune K (Hrsg.) New Pharmacological and Epidemiological Data in Analgesic Research, Adelaide, April 1990:9. Birkhäuser Verlag Basel-Boston-Berlin; 1990
    Google Scholar
  • 38 Henrich W L. Nephrotoxicity of nosteroidal antiinflammatory agents. In: Schrier RW, Gottschalk CW (eds.) Diseases of the Kidney. Little, Brown and Company Boston; 1993 5th ed.: 1203
    Google Scholar
  • 39 Henry D, Lim L, Rodriguez L, Perez Gutthann S, Carson J, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries J. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.  Br Med J. 1996;  312 1563
    CrossrefPubMedGoogle Scholar
  • 40 Hochberg M C, Altman R D, Brand K D. Guidelines for the medical management of osteoarthritis: Pt I. Osteoarthritis of the hip.  Arthritis Rheum. 1995;  38 1535
    PubMedGoogle Scholar
  • 41 Hochberg M C, Altman R D, Brand K D. Guidelines for the medical management of osteoarthritis: Pt II. Osteoarthritis of the knee.  Arthritis Rheum. 1995;  38 1541
    CrossrefPubMedGoogle Scholar
  • 42 Houston M C. Nonsteroidal anti-inflammatory drugs and antihypertensives.  Am J Med. 1991;  90 ( (suppl. 5 A)) 42
    PubMedGoogle Scholar
  • 43 Inman WHW ed Drug Safety Research Unit (Southampton). PEM News 1991 7: 32
    Google Scholar
  • 44 Jurna I. Mechanismen der Schmerzunterdrückung durch Pharmaka.  Münch Med Wschr. 1985;  127 573
    PubMedGoogle Scholar
  • 45 Lane N E. Pain management in osteoarthritis: The role of cox- 2 inhibitors.  J Rheumatol. 1997;  24 ((suppl 49)) 20-24
    PubMedGoogle Scholar
  • 46 Laine L, Harper S, Simon T, Bath R. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase- 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.  Gastroenterology . 1999;  117 ((4)) 776-783
    PubMedGoogle Scholar
  • 47 Leung F W, Miller J C, Guth P H. Dissociated effects of misoprostol on gastric acid secretion amd mucosal blood flow.  Dig Dis Sci. 1986;  31 ((suppl.)) 86S
    CrossrefPubMedGoogle Scholar
  • 48 Levi S, Goodlad R A, Lee C J. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing.  Lancet. 1990;  336 840
    CrossrefPubMedGoogle Scholar
  • 49 Levy M H. Pharmacologic treatment of cancer pain.  N Engl J Med. 1996;  10 1124
    PubMedGoogle Scholar
  • 50 Marnett L J, Chen Y N, Maddipatti K R, Ple¿ P, Labeque R. Functional differentiation of cycloxygenase an peroxidase activities of prostaglandin synthase by trypsin treatment.  J Biol Chem. 1988;  263 16 532
    PubMedGoogle Scholar
  • 51 Marnett L J, Kalgutkar A S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future.  Trends Pharmacol Sci . 1999;  20 ((11)) 465-469
    CrossrefPubMedGoogle Scholar
  • 52 Mene P, Pugliese F, Patrono G. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease.  Semin Nephrol. 1995;  15 244
    PubMedGoogle Scholar
  • 53 Morham S G, Langenbach R, Loftin C D, Tiano H F, Vouloumanos N, Jennette J C, Mahler J F, Kluckman K D, Ledford A, Lee C A, Smithies O. Prostaglandin synthase- 2 gene disruption causes severe renal pathology in the mouse.  Cell. 1995;  83 ((53)) 473
    CrossrefPubMedGoogle Scholar
  • 54 Morris A D, Holt S D, Silvoso G R. Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis: an endoscopic assessment.  Scand J Gastroenterol. 1981;  67 ((Suppl.)) 131
    PubMedGoogle Scholar
  • 55 Muller V P, Dammann H G, Simon B. Akute Schädigung der Magenschleimhaut durch Acetylsalizylsäure: eine endoskopische Vergleichsstudie mit oral wirksamen Prostaglandinanaloga, Omeprazol und Ranitidin [abstract].  Arzneimittelforschung. 1986;  36 265
    PubMedGoogle Scholar
  • 56 Nobunaga M. NSAID-induced GI damage: a serious problem?. In: Nasution AR, Darmawan J, Isbagio, (eds.) Proceedings of the 7th APLAR Congress of Rheumatology: 1992 Sep 13 - 18; Bali. 
    Google Scholar
  • 57 Oberle G P, Stahl R AK. Akute Nebenwirkungen nicht steroidaler Antiphlogistika auf die Nieren.  Dtsch med Wschr. 1990;  115 309
    PubMedGoogle Scholar
  • 58 Raskin J B, White R H, Jaszewski R. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.  Am J Gastroenterol. 1996;  91 ((2)) 223
    PubMedGoogle Scholar
  • 59 Robinson M G, Griffin J W, Bowers J. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs.  Dig Dis Sci. 1989;  34 424
    CrossrefPubMedGoogle Scholar
  • 60 Seelig C B, Maloley P A, Campbell J R. Nephrotoxicity assotiated with concomitant ACE inhibitor and NSAID therapy.  South Med J. 1990;  33 232
    PubMedGoogle Scholar
  • 61 Semble E L, Turner R A, Wu W C. Clinical and genetic characteristics of upper gastrointestinal disease in rheumatoid arthritis.  J Rheumatol. 1987;  14 692
    PubMedGoogle Scholar
  • 62 Shiokawa Y, Nobunaga M, Saito N. Epidemiology study of upper GI tract lesions induced by NSAIDs.  Ryumachi. 1991;  31 96
    PubMedGoogle Scholar
  • 63 Silverstein F E, Graham D Y, Senior J R. Misoprostol reduced serious gastrointestinal complications in patients with rheumatoid arthritis recieving nos-steroidal anti-inflammatory drugs: a randomized, double-blind placebo-controlled study.  Ann Intern Med. 1995;  123 241
    PubMedGoogle Scholar
  • 64 Silvoso G R, Ivey K J, Butt J H. Incidence of gatric lesions in patients with rheumatic disease on chronic aspirin therapy.  Ann Intern Med. 1979;  91 517
    PubMedGoogle Scholar
  • 65 Tan S Y, Shapiro R, Franco R. Indomethacin.induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism.  Ann Intern Med. 1979;  9 783
    PubMedGoogle Scholar
  • 66 Thun M J, Namboodiri M M, Heath C W. Aspirin use and reduced risk of fatal colon cancer.  N Engl J Med. 1991;  5325 ((23)) 1593-1596
    PubMedGoogle Scholar
  • 67 Taylor I N, Kenny G NC. Non-steroidal anti-inflammatory drugs.  Curr Opin Anaest. 1993;  6 696
    PubMedGoogle Scholar
  • 68 Tsuji M, Kawano S, Tsuji S. Cyclooxygenase regulates angiogenesis induced by colon cancer cells.  Cell. 1998;  93 ((5)) 705-716
    CrossrefPubMedGoogle Scholar
  • 69 Van Duin C M, Van Essen J A, Van Miert A SJPAM. Mechanism of the antipyretic action of salicylates and pyrazolone derivates.  Zbl Vet Med. 1975;  A 22 510
    PubMedGoogle Scholar
  • 70 Van Miert A SJPAM, Van Der Wal-Komproe L E, Van Duin C TM. Effects of antipyretic agents on fever and ruminal stasis induced by endotoxins in conscious goats.  Arch Int Pharmacodyn. 1977;  225 39
    PubMedGoogle Scholar
  • 71 Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like-drugs.  Nature. 1971;  231 232
    PubMedGoogle Scholar
  • 72 Ventafridda V, Tamburini M, Caraceni A, De Conno F. Naldi F. A validation study of the WHO method for cancer pain relief.  Cancer. 1987;  59 850
    CrossrefPubMedGoogle Scholar
  • 73 Walan A, Bader J P, Classen M. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.  N Engl J Med. 1989;  32 69
    PubMedGoogle Scholar
  • 74 Walt R P. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration.  N Engl J Med. 1992;  327 1575
    PubMedGoogle Scholar
  • 75 Wallace J L. Selective COX- 2 inhibitors: is the water becoming muddy?.  Trends Pharmacol Sci. 1999;  2 ((1)) 4-6
    PubMedGoogle Scholar
  • 76 Weithmann K U, Alpermann H G. Biochemical and pharmacological effects of dipyrone and ist metabolites in model systems related to arachidonic acid cascade.  Arzneim.-Forsch./Drug Res.. 1985;  35 ((I)) 947
    PubMedGoogle Scholar
  • 77 Wen S F. Nephrotoxicities of nonsteroidal anti-inflammatory drugs.  J Formos Med Assoc. 1997;  96 157
    PubMedGoogle Scholar
  • 78 World Health Organisation .Cancer Pain Relief. Office of Publications, WHO Geneva; 1986: 74
    Google Scholar
  • 79 Zech D, Schug S A. Medikamentöse Therapie. In: Hankemeier UB, Bowdler I, Zech D (Hrsg.) Tumorschmerztherapie. Springer Berlin, Heidelberg, New York; 1989
    Google Scholar
  • 80 Zenz M, Zenz T h, Tryba M, Strumpf M. Severe undertreatment of cancer pain: A 3-year survey of the german situation.  J Pain Symptom Manage. 1995;  10 187
    CrossrefPubMedGoogle Scholar

Dr. Eugen Ladner

Abteilung für Anästhesie Bezirkskrankenhaus Reutte

Krankenhausstr. 39

6600 Ehenbichl

Österreich

      >